Metraipolis › archive › dc_57acd3059641

Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study — Europe PMC PMID:41908680

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41908680
DOI
10.1093/crocol/otag018
License (as archived)
solo-consultazione
Archived
2026-11-07T06:10:05.108Z
SHA-256 of the archived text
e3f57c8208657d5857c98b51183e4525fb768b75b4bed9e94a48acf4d29e3d32
Stable URL of this page
https://metraipolis.com/documento/dc_57acd3059641

How to cite

Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study — Europe PMC PMID:41908680 — Europe PMC (en), https://europepmc.org/article/MED/41908680 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_57acd3059641 (Metraipolis archive dc_57acd3059641, sha256 e3f57c8208657d5857c98b51183e4525fb768b75b4bed9e94a48acf4d29e3d32)
BibTeX
@misc{dc57acd3059641,
  title = {Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study — Europe PMC PMID:41908680},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41908680},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_57acd3059641; sha256 e3f57c8208657d5857c98b51183e4525fb768b75b4bed9e94a48acf4d29e3d32},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41908680. Agents can read the archived copy with the MCP tool read_document.